Fig. 4
Spider plots depicting tumor responses to treatment. Solid lines represent patients with prior fluoropyrimidine exposure. Dashed lines represent fluoropyrimidine-naïve patients. Upper panel: In Part 1, 18 patients received doses of NUC-3373 between 1125 and 2500 mg/m2. Fourteen of these patients had post-baseline scans and are represented above. Lower panel: In Part 2, 16 patients received doses of NUC-3373 between 1500 and 2500 mg/m2. Twelve of these patients had post-baseline scans and are represented above